cas 3034-22-8|| where to buy 5-bromo-1,3-thiazol-2-amine

Nombre del producto:5-bromo-1,3-thiazol-2-amine

IUPAC Name:5-bromo-1,3-thiazol-2-amine

Unidad de embalaje	Stock disponible	Precio($)
CM104786-25g	in stock	ƩǺ
CM104786-100g	in stock	ŭșș
CM104786-500g	in stock	ȋǠƏ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3034-22-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :3034-22-8; Fórmula molecular:C3H3BrN2S; Punto de fusión:-; Código de sonrisas:NC1=NC=C(Br)S1; Densidad:

: Número de catálogo:CM104786; Peso molecular:179.04; Punto de ebullición:; Nº Mdl:MFCD00016893; Almacenamiento:

: Thiazoles; Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

: Cadisegliatin; vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.